The OPKO test panel will combine PSA and two novel kallikrein markers to provide greater accuracy.
The biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York.
The study results indicate that these markers can predict initial biopsy results in men suspected of having prostate cancer.
OPKO Health chairman and CEO Phillip Frost said these two new biomarkers provide them with a unique opportunity to greatly improve the value of prostate cancer screening.
"The higher specificity of our new panel of markers will provide better and more efficient outcomes, while lowering overall costs," Frost added.